Abstract
Informed consent is a requirement for medical research. Obtaining consent can be complex in patients with severe psychiatric disorders, often leading to their exclusion from study participation. Here, we discuss a case involving a patient with clozapine-resistant schizophrenia, highlighting the different perspectives of caregivers and physician-researchers, with an emphasis on decision-making capacity. The case illustrates the complexity of informed consent in this population, including the challenges in assessing decision-making capacity, ethical dilemmas, and potential improvements.
We conclude that improving existing standardized assessment tools, promoting inclusive approaches to research participation, and supporting patient representation in decision-making processes can contribute to the quality and integrity of medical research involving individuals with the most severe forms of psychiatric disorders.
Translated title of the contribution | Study participation in clozapine-resistant psychosis: a case study on decision-making capacity |
---|---|
Original language | Dutch |
Pages (from-to) | 443-446 |
Number of pages | 4 |
Journal | Tijdschrift voor Psychiatrie |
Volume | 66 |
Issue number | 8 |
Publication status | Published - Oct 2024 |